Red List:Official warnings and scam reports, with sourcesCheck a link
NewsNews

TGA Guidance on Prescription Medicine Ads Names Cannabis Clinics

The June 18, 2026 guidance covers websites, social media, business names, booking systems and price lists, and targets telehealth services that promise specific medicines.

This story is about Australia — not the country you picked in the header.

Illustration: a cannabis bud under a glass cloche
Illustration: Verdex

Key takeaways

  • On June 18, 2026 the TGA published 'Complying with the restrictions on advertising prescription medicines to the public'.
  • It lists medical cannabis alongside cosmetic injectables, peptides, weight-loss injections, IV drips and erectile dysfunction medicines as services it monitors online.
  • The guidance covers business names, logos, booking systems, product catalogues and price information.
  • Penalties reach A$1.65 million per breach for individuals and A$16.5 million per breach for corporations.
  • Six weeks later, on August 4, 2026, the TGA sued Better Leaf, Better Life Aussie and their director over cannabis advertising.

The Therapeutic Goods Administration (TGA) released Complying with the restrictions on advertising prescription medicines to the public on June 18, 2026, and updated its separate guidance on advertising health services that involve therapeutic goods, including online and telehealth services.

The clinic ads that now cross the line

Medicinal cannabis in Australia is a prescription medicine, and most of it reaches patients through telehealth clinics that compete online. The new document follows the TGA's December 2023 cannabis-specific advertising guidance and applies the same kind of tests to all prescription-medicine services, and the TGA lists medical cannabis among the services it targets.

A$16.5m

maximum civil penalty per breach for a corporation

TGA, June 18, 2026

A$1.65m

maximum civil penalty per breach for an individual

TGA, June 18, 2026

What the guidance covers

  • Channels — websites and social media, but also business names and logos.
  • Sales tools — booking systems, product catalogues and price information.
  • Service ads — promotion of health services, including telehealth, as a way to access specific prescription medicines.
  • Services named — cosmetic injectables, peptides, weight-loss injections, medical cannabis, IV drip therapies and erectile dysfunction medicines.
Before (December 2023)Now (June 2026)
Advertising guidance written specifically for medicinal cannabis businessesOne guidance document for all prescription medicines, with medical cannabis named among targeted services
Focus on product ads, synonyms such as "plant medicine" and cannabis in business namesAdds booking systems, product catalogues and price information as examples
Health-service ads must not promote access to a cannabis prescriptionUpdated health-service guidance also addresses online and telehealth services offering specific medicines

The TGA said it works for voluntary compliance first and expects businesses to review and remove non-compliant content promptly. Where it finds serious non-compliance it can issue infringement notices, directions or prevention notices, or start civil or criminal proceedings.

Enforcement since the guidance

  1. The TGA sues AG Therapeutics (Atlus), its director, Mamamia, News Life Media and a PR firm over cannabis ads and sponsored articles.

  2. ACPharm Queensland pays five infringement notices totalling A$99,000.

  3. New prescription-medicine advertising guidance published.

  4. The TGA sues Better Leaf, Better Life Aussie and their sole director, alleging ads on websites, social media and pamphlets at a dispensary, after unpaid infringement notices.

  5. The TGA starts Federal Court proceedings against the former company behind BioV8 over peptide advertising, applying the same rules outside cannabis.

Fines and court cases the TGA has signalled

We found no published judgment in any of the TGA's cannabis advertising court cases as of September 28, 2026. The first ruling will show how far courts accept the TGA's reading of euphemisms like "plant medicine". Separately, the TGA's 2026–27 business plan commits to examining reforms for closed-loop prescribe-and-supply models, Business of Cannabis reported.

What this means for patients choosing a clinic: how to read cannabis clinic ads. Enforcement records: Verdex Red List.

FAQ

What guidance did the TGA publish in June 2026?

On June 18, 2026 it published 'Complying with the restrictions on advertising prescription medicines to the public' and updated its guidance on advertising health services that involve therapeutic goods, including telehealth.

Does the TGA guidance apply to cannabis clinics?

Yes. The TGA named medical cannabis among the services whose online promotion it targets, alongside cosmetic injectables, peptides, weight-loss injections, IV drips and erectile dysfunction medicines.

What are the penalties for advertising prescription medicines in Australia?

Civil penalties reach A$1.65 million per breach for individuals and A$16.5 million per breach for corporations, and the TGA can also issue infringement notices or bring criminal proceedings.

Have courts ruled on the TGA's cannabis advertising cases?

Not that we could find as of September 28, 2026: the TGA's court-action page lists several cannabis advertising proceedings as commenced, without a published judgment.

Sources

  1. Therapeutic Goods Administration — TGA releases new guidance on advertising restrictions for prescription medicines · Jun 18, 2026
  2. Therapeutic Goods Administration — Updated medicinal cannabis guidance (replaced) · Dec 18, 2023
  3. Therapeutic Goods Administration — TGA sues Better Leaf and Better Life Aussie for alleged unlawful advertising of medicinal cannabis · Aug 4, 2026
  4. Therapeutic Goods Administration — Court action · Sep 28, 2026
  5. Therapeutic Goods Administration — ACPharm Queensland issued infringement notices for alleged unlawful advertising of therapeutic goods · Nov 3, 2025
  6. Business of Cannabis — Australia's medical cannabis reforms to target closed-loop prescribing · Sep 4, 2026
Filed underNewsAustralia

Verdex Editorial Team

Research & editing

The Verdex editorial team researches licensed cannabis sellers, strains and consumer-safety cases. Every factual claim is tied to a public source — license registers, regulator notices, lab data or published reviews — and listed on the page. We don’t accept payment for ratings, placements or removals.

More from the team How we fact-check

Was this story useful?

Comments

No comments yet

Questions, corrections or your own experience — start the conversation.

Leave a comment

A moderator reads every comment before it’s published.

Self-check · 2 minutes · private

Is cannabis becoming a problem for you?

Eight questions from CUDIT-R, a screening test used by clinicians. Your answers never leave this page.